CompoAtlas

Women's Ultra Mega Menopause Vitapak

Texto original en francés.

Producto de salud natural autorizado en Canadá

Si este producto se vendiera en Francia

Solo se calcula una cantidad diaria para una posología oral explícita para adultos, expresada por día y en una unidad sólida correspondiente a la forma del producto. No se extrapolan las unidades ambiguas, los líquidos, los polvos ni las dosis pediátricas. Una cantidad no calculada no se compara con los límites de dosis. Este análisis no constituye una autorización de venta en Francia ni una evaluación de seguridad o eficacia.

Composición

Ingrediente medicinal y fuentePor unidad posológica, según la fuenteMáximo diario, adulto
Zingiber officinale

Fuente : Rhizome

10 mgNo calculada
Vitex agnus-castus

Fuente : Fruit

30 mgNo calculada
Vitamine B6

Fuente : Chlorhydrate de pyridoxine

25 mgNo calculada
Salvia miltiorrhiza

Fuente : Racine

Relación de extracción : 4:1

Equivalente de planta seca : 30 mg

7,5 mgNo calculada
Vitex agnus-castus

Fuente : Fruit

5 mgNo calculada
Sambucus nigra

Fuente : Fruit

Relación de extracción : 4:1

Equivalente de planta seca : 20 mg

5 mgNo calculada
Camellia sinensis

Fuente : Feuille

Potencia : 50 % Polyphenols

7,5 mgNo calculada
Manganèse

Fuente : Sulfate de manganèse

4,5 mgNo calculada
Iode

Fuente : Iodure de potassium

85 mcgNo calculada
Hordeum vulgare

Fuente : Feuille

Relación de extracción : 4:1

Equivalente de planta seca : 10 mg

2,5 mgNo calculada
Inositol

Fuente : Inositol

12,5 mgNo calculada
Bioflavonoïdes d'agrumes

Fuente : Citrus paradisi - Pelure (fruit)

7,5 mgNo calculada
Bioflavonoïdes d'agrumes

Fuente : Citrus limon - Pelure (fruit)

7,5 mgNo calculada
Bioflavonoïdes d'agrumes

Fuente : Citrus sinensis - Pelure de fruit

7,5 mgNo calculada
Acide 4-aminobenzoïque

Fuente : 4-aminobenzoic acid

5 mgNo calculada
Rosa canina

Fuente : Fruit

100 mcgNo calculada
1-Carboxy-N,N,N-chlorure de triméthylméthanaminium7,5 mgNo calculada
Capsicum annuum

Fuente : Fruit

1 mgNo calculada
Malpighia glabra

Fuente : Fruit

Potencia : 25 % Vitamin C

200 mcgNo calculada
Thiamine

Fuente : Chlorhydrate de thiamine

15 mgNo calculada
Magnésium

Fuente : Oxyde de magnésium

150 mgNo calculada
Magnésium

Fuente : Magnesium hydrolyzed vegetable protein (HVP) chelate

150 mgNo calculada
Niacinamide

Fuente : Niacinamide

7,5 mgNo calculada
Calcium

Fuente : Carbonate de calcium

300 mgNo calculada
Calcium

Fuente : Produit de chléation de calcium et de PVH

300 mgNo calculada
Silicium

Fuente : Dioxyde de silicium

1 mgNo calculada
bêta-carotène

Fuente : bêta-carotène

Potencia : 1.875 UI

1.125 mcgNo calculada
Vitamine A

Fuente : Palmitate de vitamine A

Potencia : 1.250 UI

375 mcg EARNo calculada
Vitamine D

Fuente : Cholécalciférol

Potencia : 200 UI

5 mcgNo calculada
Vitamine E

Fuente : Acétate de d-alpha tocophéryle

Potencia : 50 UI

33,5 mg ATNo calculada
Vitamin K1

Fuente : Vitamine K1

7,5 mcgNo calculada
Vitamine C

Fuente : Ascorbate de calcium

150 mgNo calculada
Riboflavine

Fuente : Riboflavine

15 mgNo calculada
Niacine

Fuente : Acide nicotinique

10 mgNo calculada
Vitamine B12

Fuente : Cyanocobalamine

75 mcgNo calculada
Folate

Fuente : Acide folique

500 mcgNo calculada
Biotine

Fuente : Biotine

125 mcgNo calculada
Acide pantothénique

Fuente : D-Pantothénate de calcium

25 mgNo calculada
Zinc

Fuente : Produit de chélation de zinc et de protéine végétale hydrolysée (PVH)

5 mgNo calculada
Ginkgo biloba

Fuente : Feuille

5 mgNo calculada
Vaccinium myrtillus

Fuente : Fruit

Relación de extracción : 100:1

Equivalente de planta seca : 600 mg

6 mgNo calculada
Oenothera biennis

Fuente : Graine(s)

Potencia : 910 mg Linoleic Acid

1.300 mgNo calculada
Oenothera biennis

Fuente : Graine(s)

Potencia : 100 mg Gamma Linolenic Acid

No especificadaNo calculada
Actaea racemosa

Fuente : Racine

160 mgNo calculada
Cuivre

Fuente : Copper HVP chelate

1 mgNo calculada
Potassium

Fuente : Chlorure de potassium

15 mgNo calculada
Chrome

Fuente : Picolinate de chrome

50 mcgNo calculada
Sélénium

Fuente : Produit de chélation de sélénium et de protéine végétale hydrolysée (PVH)

50 mcgNo calculada
Boron

Fuente : Citrate de bore

350 mcgNo calculada
Molybdène

Fuente : Citrate de molybdène

20 mcgNo calculada
Vanadium

Fuente : Citrate de vanadium

15 mcgNo calculada
Choline

Fuente : Bitartrate de choline

12,5 mgNo calculada

Ingredientes no medicinales

Gélatine, Poly(éthylène glycol), Cellulose microcristalline, Laque d'aluminiium FD&C rouge n° 40, Ethylcellulose, Dioxyde de silicium, Glycérine, Stéarate de magnésium, Acide stéarique, Acide oléique, Talc, Hydroxyde d'ammonium, FD&C Blue No.2 Aluminum Lake, Poly(alcool vinylique), Dioxyde de titane, triglycérides à chaînes moyennes, Sodium alginate

Dosis recomendadas en Canadá

PoblaciónEdadCantidad por tomaFrecuencia
Adultes de sexe fémininNon précisée1 Vitapak1 Tous les jours

Usos autorizados en Canadá

A factor in the maintenance of good health. Helps in the development and maintenance of bones, cartilage, teeth and gums. Helps to maintain eyesight, membranes, immune function, healthy skin and proper muscle function. Provides support for healthy glucose metabolism. Helps to produce and repair connective tissue. Calcium intake, when combined with sufficient vitamin D, a healthy diet, and regular exercise, may reduce the risk of developing osteoporosis. An antioxidant for the maintenance of good health. Source of essential fatty acids, omega-3 fatty acids, and omega-6 fatty acids for the maintenance of good health. Helps support cognitive health and/or brain function. Helps maintain and support cardiovascular health.Used in Herbal Medicine to help relieve symptoms associated with menopause, such as hot flushes; to help support healthy mood balance during menopause; to help ease nervous tension (calmative); to help relieve pain associated with menstruation; to help relieve premenstrual symptoms.

Texto original en inglés.

Un uso autorizado en Canadá no es una declaración de propiedades saludables autorizada en la Unión Europea. Consulte el registro de declaraciones de propiedades saludables.

Advertencias en Canadá

Cautions and Warnings : Consult a health care practitioner if symptoms persist or worsen. Consult a health care practitioner prior to use if you are taking sulfonamides and/or if you have an iron deficiency; if you have stomach ulcers or inflammation; if you are taking blood thinners; if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy; if you have high blood pressure; if you are taking antidepressants. If you have a liver disorder, consult a health care practitioner prior to use. Stop use if you develop symptoms of liver trouble such as yellowing of the skin/eyes (jaundice), stomach pain, dark urine, sweating, nausea, unusual tiredness and/or loss of appetite and consult a health care practitioner.

Texto original en inglés.

Contra-Indications : Do not use if you are pregnant or breastfeeding.

Texto original en inglés.

Known Adverse Reactions : Hypersensitivity (e.g. allergy) has been known to occur; in which case, discontinue use. People sensitive to nicotinic acid may experience flushing of the skin that is generally mild and transient. Rare, unpredictable cases of liver injury associated with green tea extract-containing products have been reported (in Canada and internationally).

Texto original en inglés.

Ficha del producto

Titular
GNC Canada Holdings ULC
NPN o DIN-HM
80051771
Estado
Licencia no activa
Fecha de licencia
13 de junio de 2014
Fecha de revisión
No indicada
Forma
Kit
Vía de administración
Orale
Tipo de solicitud
Non traditionnelle

Fuente

Ficha oficial de Health Canada, licencia 80051771

Base de datos de productos de salud natural autorizados (BDPSNH), Health Canada: productos autorizados, ingredientes, dosis, usos y advertencias, consultado el 27 de octubre de 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Texto original en inglés.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Texto original en francés.

La fórmula vendida en Europa con el mismo nombre puede ser diferente. Esta información no sustituye el consejo de un médico o farmacéutico.

Advertencias oficiales (Health Canada)

Health Canada publica advertencias sobre estos ingredientes:

  • Zingiber officinale
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    GINGER - ZINGIBER OFFICINALE

    Vía de administración: Oral

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 19 de diciembre de 2025

  • Vitex agnus-castus
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    CHASTE TREE - VITEX AGNUS-CASTUS

    Vía de administración: Oral (WHO 2009; Bradley 2006; Mills and Bone 2000)

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy (Brinker 2010; WHO 2009; Bradley 2006).

    Fuentes citadas por Health Canada (4)
    • Bradley PR, editor. 2006. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
    • OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.

    Contraindicaciones

    Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a health care practitioner/health care provider/health care professional/doctor/physician (EMA 2018; Najib et al. 2022; Brinker 2010; WHO 2009; Dugoua et al. 2008; ESCOP 2003; Blumenthal 2000; Mills and Bone 2000).

    Fuentes citadas por Health Canada (9)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. 2000. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Dugoua JJ, Seely D, Pern D, Koren G, Mills E. Safety and efficacy of chastetree (Vitex Agnus-Castus) during pregnancy and lactation. Can J. Clin Pharmacol 2008;15(1);e74-e79.
    • EMA 2018. European Medicines Agency. European Union herbal monograph on Vitex agnus-castus L., fructus. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 27 March 2018. [Accessed 2024 February 29] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-vitex-agnus-castus-l-fructus-revision-1_en.pdf
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy in collaboration with Thieme.
    • Mills S, Bone K. 2000. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone.
    • Najib FS, Poordast T, Mahmudi MS, Shiravani Z, Namazi N, Omrani GR. Does Vitex Agnus-Castus L. Have Deleterious Effect on Fertility and Pregnancy Outcome? An Experimental Study on Rats for Prediction of Its Safety. J. Pharmacopuncture 2022;25(2):106-113. PubMed
    • WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
    • OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.

    Monografía de Health Canada del 28 de marzo de 2024

  • Sambucus nigra
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    ELDER – SAMBUCUS

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Condición de aplicación: Diaphoretic; Symptoms of colds, flus; Sinusitis, hay-fever; Joint pain.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Reacciones adversas conocidas

    Condición de aplicación: All products.

    Stop use if hypersensitivity/allergy occur (Forster-Waldl et al. 2003).

    Fuentes citadas por Health Canada (1)
    • Förster-Waldl E, Marchetii M, Schöll I, Focke M, Radauer C, Kinaciyan T, Nentwich I, Jäger S, Schmid ER, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E. Type I allergy to elderberry (Sambucus nigra) is elicited by a 33.2 kDa allergen with significant homology to ribosomal inactivating proteins. Clinical and Experimental Allergy 2003;33(2):1703-1710. PubMed

    Condición de aplicación: All products except those making a diuretic claim.

    When using this product diuretic effect may occur (Bradley 1992; Winston and Kuhn 2008; Barnes et al. 2007; Hoffman 2003).

    Fuentes citadas por Health Canada (2)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines. 3rd edition. London (GB): The Pharmaceutical Press; 2007.
    • Winston D and Kuhn MA. Herbal Therapy & Supplements A Scientific and Traditional Approach. Philadelphia (PA): Lippincott Williams & Wilkins; 2008.

    2 estudios citados en el texto no tienen referencia correspondiente en la monografía (véanse las anomalías en la página de fuentes).

    Monografía de Health Canada del 19 de diciembre de 2025

  • Capsicum annuum
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    CAYENNE - CAPSICUM ANNUUM Oral

    Precauciones y advertencias

    Condición de aplicación: All products.

    Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).

    Fuentes citadas por Health Canada (1)
    • CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).

    Fuentes citadas por Health Canada (2)
    • Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).

    Fuentes citadas por Health Canada (1)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Condición de aplicación: Digestion; Peripheral circulation.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 27 de marzo de 2026

    CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical

    Precauciones y advertencias

    Condición de aplicación: All products.

    For external use only (US FDA 2023).

    Fuentes citadas por Health Canada (1)
    • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

    1 estudio citado en el texto no tiene referencia correspondiente en la monografía (véanse las anomalías en la página de fuentes).

    When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).

    Fuentes citadas por Health Canada (1)
    • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

    1 estudio citado en el texto no tiene referencia correspondiente en la monografía (véanse las anomalías en la página de fuentes).

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).

    Fuentes citadas por Health Canada (1)
    • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

    1 estudio citado en el texto no tiene referencia correspondiente en la monografía (véanse las anomalías en la página de fuentes).

    Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).

    Fuentes citadas por Health Canada (1)
    • CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Reacciones adversas conocidas

    Condición de aplicación: All products.

    Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).

    Fuentes citadas por Health Canada (5)
    • APhA 2002: Berardi RR, DeSimone EM, Newton GGD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An interactive approach to self-care. 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • Brayfield A, Cadart C, editors. Martindale: The Complete Drug Reference. London (GB): Pharmaceutical Press; 2024. [Accessed 2024 August 14]. Available from: https://www.medicinescomplete.com/#/browse/martindale
    • Hoffman D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press; 2003.
    • McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. British Journal of Clinical Pharmacology 2000;49:574-579. PubMed Ensayo aleatorizado
    • Zhang W, Moskowitz, RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 2008;16:137-162. PubMed Revisión sistemática

    Monografía de Health Canada del 27 de marzo de 2026

  • Vitamine D
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    VITAMIN D (>1,000 - 2,500 IU)

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: All products except products containing zinc sourced from picolinate requiring a contraindication.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney disorders (NIH 2024; BfR 2020).

    Fuentes citadas por Health Canada (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking other supplements or products containing vitamin D or vitamin D analogues.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any medications including antacids, anticonvulsants, digoxin, cholestyramine, colestipol, mineral oil, steroids, statins or thiazide diuretics (NNHPD 2021; BfR 2020).

    Fuentes citadas por Health Canada (3)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NNHPD 2021. Natural and Non-Prescription Health Products Directorate. Internal evidence and HC's product monographs.
    • DPSNSO 2021. Direction des produits de santé naturels et sans ordonnance. Preuves internes et monographies de produits internes de SC.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to determine if you would benefit from additional vitamin D as 15-20 mcg (600-800 IU) of vitamin D per day is an adequate quantity for most individuals.

    Se aplica a los productos: containing vitamin K2.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (NNHPD 2026).

    Fuentes citadas por Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Se aplica a los productos: providing 25-34 mg of zinc per day for adults 18 years or 31-50 mg of zinc per day for adults 19 years and older.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are unsure whether you are taking enough copper as zinc supplementation can cause a copper deficiency (NNHPD 2026).

    Fuentes citadas por Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Contraindicaciones

    Condición de aplicación: All products.

    Do not use if you have hypercalcemia and/or hypercalciuria (NIH 2024; BfR 2020).

    Fuentes citadas por Health Canada (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Se aplica a los productos: containing zinc sourced from picolinate.

    Do not use if you are pregnant or breastfeeding (NNHPD 2026).

    Fuentes citadas por Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Reacciones adversas conocidas

    Condición de aplicación: All products.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if the following early symptoms of hypercalcemia occur: weakness, fatigue, drowsiness, headache, lack of appetite, dry mouth, metallic taste, nausea, vomiting, vertigo, ringing in the ears, lack of coordination and muscle weakness or if you develop any other symptom (NIH 2024; BfR 2020).

    Fuentes citadas por Health Canada (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Se aplica a los productos: providing more than 350 mg of magnesium per day.

    When using this product you may experience diarrhea (NNHPD 2026).

    Fuentes citadas por Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Monografía de Health Canada del 26 de junio de 2026

  • Ginkgo biloba
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    GINKGO - GINKGO BILOBA

    Vía de administración: Oral

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Blumenthal et al. 2000; WHO 1999).

    Fuentes citadas por Health Canada (3)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Newton (MA): Integrative Medicine Communications; 2000.
    • WHO 1999: World Health Organization. WHO monographs on selected medicinal plants, Volume 1. Geneva (CHE): World Health Organization; 1999.
    • OMS 1999 : Organisation mondiale de la santé (OMS). Monographs on selected medicinal plants, Volume 1. Genève (CHE): Organisation mondiale de la santé; 1999.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking diabetes, high blood pressure or seizure medications (Brinker 2010).

    Fuentes citadas por Health Canada (1)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Contraindicaciones

    Do not use if you are having a surgery (Gardner and McGuffin 2013).

    Fuentes citadas por Health Canada (1)
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.

    Do not use if you are taking blood thinners or other health products that affect blood coagulation (Gardner and McGuffin 2013; Brinker 2010; Bent 2005).

    Fuentes citadas por Health Canada (3)
    • Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. Journal of General Internal Medicine 2005;20(7):657-661. PubMed Revisión sistemática
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.

    Monografía de Health Canada del 25 de julio de 2025

  • Vaccinium myrtillus
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    BILBERRY - VACCINIUM MYRTILLUS - Buccal

    Vía de administración: Buccal (Blumenthal et al. 2000)

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 30 de enero de 2026

    BILBERRY - VACCINIUM MYRTILLUS - Oral

    Vía de administración: Oral (Blumenthal et al. 2000)

    Precauciones y advertencias

    Condición de aplicación: Relief of diarrhea.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condición de aplicación: Slowing the progression of disorders of the eye and to relieve symptoms related to non-complicated CVI.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Monografía de Health Canada del 25 de octubre de 2024

  • Oenothera biennis
    Leer la advertencia, cuándo se aplica y los estudios citados
  • Actaea racemosa
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    Black Cohosh - Actaea Racemosa

    Vía de administración: Oral

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver disorder or develop symptoms of liver trouble (EMA 2018, 2007; Lynch et al. 2006; Mills et al. 2006; Cohen et al. 2004; NIH 2004).

    Fuentes citadas por Health Canada (6)
    • Cohen SM, O'Connor AM, Hart J, Merel NH, Te HS. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause: the Journal of the North American Menopause Society 2004;11(5):575-577. PubMed Caso clínico
    • EMA 2018: European Medicines Agency. Committee on Herbal Medicinal Products (HMPC). European Union Herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizome. March 2018. [Accessed 2025 January 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cimicifuga-racemosa-l-nutt-rhizome-revision-1_en.pdf
    • EMA 2007: European Medicines Agency. Committee on Herbal Medicinal Products (HMPC) Annex 1. Assessment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (Black cohosh, root). London (UK): European Medicines Agency; May 20027. [Accessed 2025 January 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-report/assessment-case-reports-connected-herbal-medicinal-products-containing-cimicifugae-racemosae-rhizoma-black-cohosh-root_en.pdf
    • Lynch CR, Folkers ME, Hutson WR. Fulminant hepatic failure associated with the use of black cohosh: a case report. Liver Transplantation 2006;12(6):989-992. PubMed Caso clínico
    • Mills E, Duguoa J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation. New York (NY): Taylor and Francis; 2006.
    • NIH 2004: National Institutes of Health. Workshop on the Safety of Black Cohosh in Clinical Studies. Bethesda (MD): National Institutes of Health, Department of Health and Human Services; November 22, 2004. [Accessed 2024 December 3]. Available from: https://files.nccih.nih.gov/s3fs-public/news/blackcohosh_mtngsumm.pdf

    Contraindicaciones

    Do not use if you are pregnant (Brinker 2010; Hoffmann 2003; Tilgner 1999).

    Fuentes citadas por Health Canada (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.
    • Tilgner S. Herbal Medicine from the Heart of the Earth Creswell (OR): Wise Acre Press; 1999.

    Monografía de Health Canada del 31 de enero de 2025

Se refieren al ingrediente, no a este producto ni a su dosis. No sustituyen el consejo médico.

Se desconoce la fecha de la prueba de esta lista de ingredientes.

¿Ha cambiado el producto? Fotografíe el envase.

¿Alguna información inexacta o más reciente sobre este producto, sea usted lector o marca? Escriba a contact@compoatlas.com: cada corrección se publica en el registro de correcciones.

Intro para analizar, Mayús+Intro para una nueva línea